Fulgent Genetics, Inc. FLGT
26.15 USD +2.41 (+10.15%)
At closeNov 9, 2026, 4:00 PM EST
26.15 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
23.32 Day range 26.66
13.79 52-week range 30.85
- YTD
- -0.46%
- 1 year
- -0.80%
News
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
marketbeat.com What Fulgent Genetics (FLGT) Said on Its Q3 Earnings Call Fulgent Genetics NASDAQ: FLGT reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift…
benzinga.com Fulgent Genetics Q3 2026 Earnings Call Transcript Fulgent Genetics (NASDAQ:FLGT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Fulgent Genetics Raises FY2026 Adj EPS Guidance from $(2.35)-$(2.22) to $(1.75)-$(1.65) vs $(2.27) Est; Affirms FY2026 Sales Guidance of $330.000M-$340.000M vs $331.700M Est Fulgent Genetics (NASDAQ:FLGT) raises FY2026 Adj EPS guidance from $(2.35)-$(2.22) to $(1.75)-$(1.65) vs $(2.27) analyst estimate. Affirms FY2026 sales outlook from $330.000 million-$340.000 million…
benzinga.com Fulgent Genetics Q3 Adj. EPS $(0.09) Beats $(0.65) Estimate, Sales $90.412M Beat $86.300M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.65) by 86.15 percent. This is a 164.29 percent decrease over earnings of…
benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $15 to $19.
benzinga.com Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
benzinga.com Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M to $330.000M-$340.000M vs $351.900M Est Fulgent Genetics (NASDAQ:FLGT) lowers FY2026 Adj EPS guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) analyst estimate. Lowers FY2026 sales outlook from $350.000 million to $330.000…
benzinga.com Fulgent Genetics Q2 Adj. EPS $(0.58) Misses $(0.46) Estimate, Sales $85.389M Miss $94.000M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 928.57 percent decrease over earnings…- benzinga.com Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety Profile Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today…
benzinga.com Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15 Piper Sandler analyst David Westenberg reiterates Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $30 to $15.
benzinga.com Full Transcript: Fulgent Genetics Q1 2026 Earnings Call 
benzinga.com Earnings Scheduled For May 1, 2026 
benzinga.com Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares up 21% on Q4 earnings.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Dow Dips Over 600 Points; US Producer Prices Increase In January US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in January.
benzinga.com Fulgent Genetics Sees FY2026 Adj EPS $(1.45) vs $(0.32) Est; Sees Sales $350.000M vs $356.333M Est Fulgent Genetics (NASDAQ:FLGT) is looking for FY2026 Adj EPS of $(1.45) vs $(0.32) analyst estimate. sees sales of $350.000 million vs $356.333 million analyst estimate.
benzinga.com Fulgent Genetics Q4 Earnings Assessment - benzinga.com Fulgent Genetics Q4 Adj. EPS $0.16 Beats $0.03 Estimate, Sales $83.336M Miss $85.381M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.03 by 433.33 percent. This is a 300 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 27, 2026
benzinga.com Earnings Preview: Fulgent Genetics - benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $30 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $21 to $30.
benzinga.com Fulgent Genetics Raises FY2025 GAAP EPS Guidance from $(2.10) to $(1.70) vs $(1.94) Est Fulgent Genetics (NASDAQ:FLGT) raises FY2025 GAAP EPS guidance from $(2.10) to $(1.70) vs $(1.94) analyst estimate..
benzinga.com Fulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.35) to $0.30 vs $(0.35) Est; Raises FY2025 Sales Guidance from $320.000M to $325.000M vs $320.118M Est Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.35) to $0.30 vs $(0.35) analyst estimate. Raises FY2025 sales outlook from $320.000 million to $325.000 million vs $320.118…- benzinga.com Fulgent Genetics Q3 Adj. EPS $0.14 Beats $(0.22) Estimate, Sales $84.069M Beat $81.431M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.22) by 162.78 percent. This is a 54.84 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 7, 2025 - benzinga.com Fulgent Genetics's Earnings Outlook
- benzinga.com Fulgent Genetics Reports Phase 2 Cancer Drug Results Ahead Of ESMO 2025 Presentation Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today…
- benzinga.com UBS Upgrades Fulgent Genetics to Buy, Raises Price Target to $30 UBS analyst Lu Li upgrades Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raises the price target from $20 to $30.
- benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $21 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $23 to $21.
benzinga.com Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Fulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.65) to $(0.35) vs $(0.55) Est; Raises FY2025 Sales Guidance from $310.000M to $320.000M vs $310.682M Est Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.65) to $(0.35) vs $(0.55) analyst estimate. Raises FY2025 sales outlook from $310.000 million to $320.000 million vs $310.682…
- benzinga.com Fulgent Genetics Q2 Adj. EPS $0.07 Beats $(0.18) Estimate, Sales $81.803M Beat $76.205M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.18) by 138.25 percent. This is a 53.33 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For August 1, 2025
- benzinga.com Fulgent Genetics Earnings Preview
- benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $23 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $16 to $23.
- benzinga.com Raymond James Reiterates Outperform on Fulgent Genetics, Raises Price Target to $25 Raymond James analyst Andrew Cooper reiterates Fulgent Genetics (NASDAQ:FLGT) with a Outperform and raises the price target from $24 to $25.
- benzinga.com Fulgent Genetics Affirms FY2025 GAAP EPS Guidance of $(1.95) vs $(1.34) Est Fulgent Genetics (NASDAQ:FLGT) affirms FY2025 GAAP EPS guidance from $(1.95) to $(1.95) vs $(1.34) analyst estimate..
benzinga.com Fulgent Genetics Affirms FY2025 Adj EPS Guidance of $(0.65) vs $(0.66) Est; Affirms FY2025 Sales Guidance of $310.00M vs $310.44M Est Fulgent Genetics (NASDAQ:FLGT) affirms FY2025 Adj EPS guidance from $(0.65) to $(0.65) vs $(0.66) analyst estimate. Affirms FY2025 sales outlook from $310.00 million to $310.00 million vs $310.44…- benzinga.com Fulgent Genetics Q1 Adj. EPS $0.04 Beats $(0.18) Estimate, Sales $73.46M Beat $71.26M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.18) by 122.22 percent. This is a 500 percent increase over losses of…
- benzinga.com Earnings Scheduled For May 2, 2025
- benzinga.com A Peek at Fulgent Genetics's Future Earnings
- benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $16 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $22 to $16.
- benzinga.com Fulgent Genetics Q4 Adj $0.04 Beats $(0.12) Estimate, Sales $76.21M Beat $75.39M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.12) by 133.33 percent. This is a 85.71 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For February 28, 2025
- benzinga.com Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $22 Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $26 to $22.
- benzinga.com Fulgent Genetics Raises FY24 Adj EPS Guidance from $(0.30) to $0.33 vs $(0.39) Est; Affirms Sales Guidance Of $280.00M vs $282.16M Est Outlook:For the full year 2024, Fulgent expects:Core Revenue of approximately $280 millionGAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per shareNon-GAAP loss…
- benzinga.com Fulgent Genetics Q3 2024 Adj. EPS $0.31 Beats $(0.15) Estimate, Sales $71.740M Beat $71.718M Estimate Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(0.15) by 306.67 percent. This is a 179.49 percent increase over losses of…